Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Coherus Oncology ( CHRS ) is a small-cap oncology company that has given me optimism, particularly as they have leveraged asset sales to fund ongoing research while also maintaining a commercial pipeline, as II have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of inve ...